234 related articles for article (PubMed ID: 24010910)
1. Positron emission tomography/computed tomography in melanoma.
Bourgeois AC; Chang TT; Fish LM; Bradley YC
Radiol Clin North Am; 2013 Sep; 51(5):865-79. PubMed ID: 24010910
[TBL] [Abstract][Full Text] [Related]
2. Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node.
Wagner T; Meyer N; Zerdoud S; Julian A; Chevreau C; Payoux P; Courbon F
Br J Dermatol; 2011 Jun; 164(6):1235-40. PubMed ID: 21332457
[TBL] [Abstract][Full Text] [Related]
3. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma.
Clark PB; Soo V; Kraas J; Shen P; Levine EA
Arch Surg; 2006 Mar; 141(3):284-8. PubMed ID: 16549694
[TBL] [Abstract][Full Text] [Related]
4. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm.
Maubec E; Lumbroso J; Masson F; Suciu V; Kolb F; Mamelle G; Cavalcanti A; Boitier F; Spatz A; Aupérin A; Leboulleux S; Avril MF
Melanoma Res; 2007 Jun; 17(3):147-54. PubMed ID: 17505260
[TBL] [Abstract][Full Text] [Related]
5. Desmoplastic malignant melanoma evaluated with 18F-fluorodeoxyglucose positron emission tomography-computed tomography and sentinel lymph node biopsy.
Jung JY; Roh MR; Chung HJ; Chung KY
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):126-7. PubMed ID: 18181996
[No Abstract] [Full Text] [Related]
6. Fluorodeoxyglucose-positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients.
Longo MI; Lázaro P; Bueno C; Carreras JL; Montz R
Dermatol Surg; 2003 Mar; 29(3):245-8. PubMed ID: 12614417
[TBL] [Abstract][Full Text] [Related]
7. Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma. A pilot study.
Klein M; Freedman N; Lotem M; Marciano R; Moshe S; Gimon Z; Chisin R
Nuklearmedizin; 2000; 39(3):56-61. PubMed ID: 10834191
[TBL] [Abstract][Full Text] [Related]
8. Considerations on 18FDG PET/CT and sentinel lymph node biopsy in AJCC stages I and II of melanoma.
Veronesi G; Ravaioli GM; Lambertini M; Zannetti G; Diodato S; Gardini A; Patrizi A; Fanti S; Dika E
G Ital Dermatol Venereol; 2020 Dec; 155(6):784-786. PubMed ID: 29998716
[No Abstract] [Full Text] [Related]
9. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
10. [Role of FDG PET-CT in cutaneous melanoma].
Nicol I; Chuto G; Gaudy-Marqueste C; Brenot-Rossi I; Grob JJ; Richard MA
Bull Cancer; 2008 Nov; 95(11):1089-101. PubMed ID: 19036682
[TBL] [Abstract][Full Text] [Related]
11. Guidelines for lymphoscintigraphy and F18 FDG PET scans in melanoma.
Uren RF; Howman-Giles R; Chung D; Thompson JF
J Surg Oncol; 2011 Sep; 104(4):405-19. PubMed ID: 21858836
[TBL] [Abstract][Full Text] [Related]
12. Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma.
Singh B; Ezziddin S; Palmedo H; Reinhardt M; Strunk H; Tüting T; Biersack HJ; Ahmadzadehfar H
Melanoma Res; 2008 Oct; 18(5):346-52. PubMed ID: 18781133
[TBL] [Abstract][Full Text] [Related]
13. The role of FDG-PET-CT is limited in initial staging of nodal metastasis for thin cutaneous melanoma.
Cheng D; McNicoll CF; Kirgan D; Jones MS; Rivera MR; Doyle GM; De Guzman MD; Baynosa J; St Hill CR
Am J Surg; 2021 Apr; 221(4):737-740. PubMed ID: 32354604
[TBL] [Abstract][Full Text] [Related]
14. [PET scanning for malignant melanoma and positive sentinel node diagnostics].
Horn J; Sjøstrand H; Lock-Andersen J; Loft A
Ugeskr Laeger; 2010 Apr; 172(15):1126-30. PubMed ID: 20427004
[TBL] [Abstract][Full Text] [Related]
15. Futility of positron emission tomography and other modalities in the initial radiographic screening of patients with melanoma.
Miranda EP
Arch Surg; 2006 Oct; 141(10):1050. PubMed ID: 17043288
[No Abstract] [Full Text] [Related]
16. Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit.
Constantinidou A; Hofman M; O'Doherty M; Acland KM; Healy C; Harries M
Melanoma Res; 2008 Feb; 18(1):56-60. PubMed ID: 18227709
[TBL] [Abstract][Full Text] [Related]
17. Melanoma imaging with highly specific PET probes: ready for prime time?
Minn H; Vihinen P
J Nucl Med; 2011 Jan; 52(1):5-7. PubMed ID: 21149485
[No Abstract] [Full Text] [Related]
18. PET/Computed Tomography and Patient Outcomes in Melanoma.
Rohren EM
PET Clin; 2015 Apr; 10(2):243-54. PubMed ID: 25829089
[TBL] [Abstract][Full Text] [Related]
19. No benefit in staging fluorodeoxyglucose-positron emission tomography in clinically node-negative head and neck cutaneous melanoma.
Bikhchandani J; Wood J; Richards AT; Smith RB
Head Neck; 2014 Sep; 36(9):1313-6. PubMed ID: 23956077
[TBL] [Abstract][Full Text] [Related]
20. The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence.
Abbott RA; Acland KM; Harries M; O'Doherty M
Melanoma Res; 2011 Oct; 21(5):446-9. PubMed ID: 21849913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
